1. Signaling Pathways
  2. Cytoskeleton
  3. Myosin

Myosin

Myosins are mechanoenzymes that interact with actin filaments and hydrolyse ATP to generate movement and force. This enables myosins to propel the sliding of actin filaments, to produce tension on actin filaments and to walk along these filaments. As a result, myosins can regulate the structure and dynamics of the actin cytoskeleton and affect the localization and transport of cellular components. The different myosins are grouped into classes on the basis of their motor domains. There are 35 known classes of myosin, and humans have 40 myosin genes that fall into 13 classes (I, II, III, V, VI, VII, IX, X, XV, XVI, XVIII, XIX and XXXV).

Myosins are actin-dependent motors that participate in a diverse range of crucial activities, including muscle contraction, intracellular trafficking, cell division, motility, actin cytoskeletal organisation and cell signaling. Myosin malfunction has been implicated in a variety of disorders including deafness, hypertrophic cardiomyopathy, Usher syndrome, Griscelli syndrome and cancer.

Myosin light chain kinase (MLCK) is an enzyme that activates the myosin light chain to exert its function related to cytoskeleton contraction and tight junction regulation. In most cells, MLCK is a transducer for signalling MLC phosphorylation in response to Ca2+ binding to MLCK-associated calmodulin. MLCK-mediated MLC phosphorylation and actomyosin contractility is important in muscle contraction, cell migration, and endo/exocytic processes, and is recognized for its central role in signalling endothelial cell-cell adhesion and barrier function.

Myosin Related Products (17):

Cat. No. Product Name Effect Purity
  • HY-13441
    (-)-Blebbistatin Inhibitor ≥98.0%
    (-)-Blebbistatin is a selective inhibitor of the ATPase activity of non-muscle myosin II.
  • HY-15417
    ML-7 hydrochloride Inhibitor 99.75%
    ML-7 hydrochloride is a naphthalene sulphonamide derivative, potently inhibits MLCK (IC50=300 nM). ML-7 hydrochloride also inhibits YAP/TAZ.
  • HY-109037
    Mavacamten Modulator ≥99.0%
    Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
  • HY-14233
    Omecamtiv mecarbil Activator 98.89%
    Omecamtiv mecarbil (CK-1827452) is a selective cardiac myosin activator.
  • HY-100685
    MS-444 Inhibitor 99.13%
    MS-444 inhibits the activity of purified smooth muscle myosin light chain kinase (MLCK) with an IC50 value of 10 μM.
  • HY-109128
    Danicamtiv Activator 99.49%
    Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency.
  • HY-100912
    W-7 hydrochloride Inhibitor 99.65%
    W-7 hydrochloride is a selective calmodulin antagonist. W-7 hydrochloride inhibits the Ca2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 µM, respectively. W-7 hydrochloride induces apoptosis and has antitumor activity.
  • HY-13813
    Blebbistatin Inhibitor
    Blebbistatin is a selective non-muscle myosin II (NMII) inhibitor, promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function.
  • HY-16690
    BTS Inhibitor ≥98.0%
    BTS (N-Benzyl-p-toluenesulfonamide) is a potent and selective inhibitor of skeletal muscle myosin II subfragment 1 (S1) ATPase activity, with an IC50s of ~5 µM for actin- and Ca2+-stimulated myosin S1 ATPase. BTS specifically inhibits the contraction of fast skeletal muscle fibers.
  • HY-100948B
    ATM-3507 trihydrochloride Inhibitor 98.10%
    ATM-3507 trihydrochloride is a potent tropomyosin inhibitor with IC50s from 3.83-6.84 μM in human melanoma cell lines.
  • HY-P1029
    MLCK inhibitor peptide 18 Inhibitor 99.66%
    MLCK inhibitor peptide 18 is a myosin light chain kinase (MLCK) inhibitor with an IC50 of 50 nM, and inhibits CaM kinase II only at 4000-fold higher concentrations.
  • HY-100984
    HA-100 Inhibitor 99.77%
    HA-100 is an inhibitor of cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase with IC50s of 4, 8, 12 and 240 μM, respectively.
  • HY-100932
    ML-9 Inhibitor 99.36%
    ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation.
  • HY-120870
    para-Nitroblebbistatin Inhibitor
    para-Nitroblebbistatin is a non-cytotoxic, photostable, fluorescent and specific Myosin II inhibitor, usd in the study of the specific role of myosin II in physiological, developmental, and cell biological studies.
  • HY-100948
    ATM-3507 Inhibitor
    ATM-3507 is a potent tropomyosin inhibitor with IC50s from 3.83-6.84 μM in human melanoma cell lines.
  • HY-107657
    (+)-Blebbistatin Inhibitor
    (+)-Blebbistatin is the inactive enantiomer of (–)-Blebbistatin. (–)-Blebbistatin is a selective inhibitor of myosin II ATPase.
  • HY-100932A
    ML-9 Free Base Inhibitor
    ML-9 (Free Base) is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 (Free Base) inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 (Free Base) induces autophagy by stimulating autophagosome formation and inhibiting their degradation.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.